| Name | Title | Contact Details |
|---|---|---|
Allisyn Monteleone |
Associate General Counsel | Profile |
Arya Sadeghi |
Senior Counsel | Profile |
Laura Brake |
Associate General Counsel | Profile |
Matt Bennett |
Head of Sales, Teliso-V | Profile |
Paul Hammond |
Associate General Counsel | Profile |
It`s all about the experience. Everything we do is about simplifying and making things better and easier. It`s about making a difference in people`s lives.
Bringing to market revolutionary laparoscopic technologies which extend the benefits of minimally invasive surgery to hundreds of millions of people worldwide.
Quorum Review IRB is an AAHRPP accredited ethics review board. Our mission is to protect patient safety while providing best-in-class customer service.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.